1. Home
  2. INDV vs HAE Comparison

INDV vs HAE Comparison

Compare INDV & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Indivior PLC

INDV

Indivior PLC

HOLD

Current Price

$33.62

Market Cap

4.1B

Sector

Health Care

ML Signal

HOLD

Logo Haemonetics Corporation

HAE

Haemonetics Corporation

HOLD

Current Price

$62.13

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INDV
HAE
Founded
N/A
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.1B
3.9B
IPO Year
2014
1996

Fundamental Metrics

Financial Performance
Metric
INDV
HAE
Price
$33.62
$62.13
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$86.00
AVG Volume (30 Days)
1.6M
910.4K
Earning Date
06-08-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
102.13
44.54
EPS
0.85
2.46
Revenue
$1,188,000,000.00
$910,373,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$5.46
P/E Ratio
$39.56
$25.34
Revenue Growth
8.69
N/A
52 Week Low
$8.34
$47.32
52 Week High
$38.00
$87.32

Technical Indicators

Market Signals
Indicator
INDV
HAE
Relative Strength Index (RSI) 47.11 41.76
Support Level $33.15 $48.91
Resistance Level $36.07 $68.77
Average True Range (ATR) 1.18 2.23
MACD -0.08 0.88
Stochastic Oscillator 42.95 62.26

Price Performance

Historical Comparison
INDV
HAE

About INDV Indivior PLC

Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.

About HAE Haemonetics Corporation

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Share on Social Networks: